...
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >D-Dimer versus International Normalized Ratio of Prothrombin Time in Ischemic Stroke Patients Treated with Sufficient Warfarin
【24h】

D-Dimer versus International Normalized Ratio of Prothrombin Time in Ischemic Stroke Patients Treated with Sufficient Warfarin

机译:足够的华法令治疗缺血性卒中患者的D-二聚体与凝血酶原时间的国际标准化比率

获取原文
获取原文并翻译 | 示例

摘要

Background: In patients receiving chronic warfarin therapy, the international normalized ratio of prothrombin time (PT-INR) reportedly correlates with the incidence, size, severity, and outcome of ischemic stroke, and thus there are guidelines for the optimal PT-INR range that is to be maintained during secondary or primary prevention of ischemic stroke. However, the details of ischemic stroke in patients in whom an optimal PT-INR is maintained by warfarin therapy have not been thoroughly investigated. We conducted a retrospective study to determine the predictors of the size, severity, and outcome of ischemic stroke occurring in patients under chronic warfarin therapy and maintenance of an optimum PT-INR. Methods: The study group comprised 22 consecutive acute ischemic stroke patients who were receiving warfarin and whose PT-INR was within the optimal range on admission. The PT-INR and plasma D-dimer level of these patients on admission were analyzed in relation to infarction volume, National Institutes of Health Stroke Scale score on admission, and modified Rankin Scale score at discharge. Results: PT-INR did not correlate with infarction volume, severity, or outcome. The D-dimer level correlated positively and significantly with the volume (r=.49, P<.05), severity (r=.54, P<.05), and outcome of ischemic stroke (r=.61, P<.01) and did not correlate with the PT-INR (r=-.27, P=.23). Conclusions: When the PT-INR is within optimal range in patients receiving chronic warfarin therapy but who suffer an ischemic stroke, the admission D-dimer level, but not PT-INR, correlates with the size, severity, and outcome of the stroke. Thus, monitoring the D-dimer level in patients receiving long-term warfarin therapy is important, regardless of whether the optimal PT-INR is maintained. (C) 2016 National Stroke Association. Published by Elsevier Inc. All rights reserved.
机译:背景:据报道,在接受慢性华法林治疗的患者中,凝血酶原时间的国际标准化比率(PT-INR)与缺血性卒中的发生率,大小,严重程度和结局相关,因此,存在最佳的PT-INR范围指南在继发性或一级预防缺血性中风期间应保持“正常”。但是,对于通过华法林疗法维持最佳PT-INR的患者,缺血性中风的细节尚未彻底研究。我们进行了一项回顾性研究,以确定在接受长期华法林治疗并维持最佳PT-INR的患者中发生缺血性卒中的大小,严重性和结果的预测因子。方法:研究组包括22名接受华法令的急性缺血性中风患者,他们的PT-INR均在入院时的最佳范围内。分析这些患者入院时的PT-INR和血浆D-二聚体水平与梗死体积,入院时美国国立卫生研究院卒中量表评分以及出院时改良的兰金量表得分的相关性。结果:PT-INR与梗死面积,严重程度或预后无关。 D-二聚体水平与体积(r = .49,P <.05),严重程度(r = .54,P <.05)和缺血性中风的结果(r = .61,P < 0.01),并且与PT-INR不相关(r =-。27,P = .23)。结论:当接受慢性华法林治疗但患有缺血性中风的患者中PT-INR在最佳范围内时,入院D-二聚体水平而非PT-INR与中风的大小,严重程度和结果相关。因此,无论是否维持最佳PT-INR,监测长期接受华法林治疗的患者的D-二聚体水平都很重要。 (C)2016年全国中风协会。由Elsevier Inc.出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号